Kamada Ltd.

Regulatory Filings • Dec 8, 2025

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in R false

����� ��"�	2 380
KAMADA LTD
Corporation no: 511524605	16035
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	08/12/2025
	www.isa.gov.il			www.tase.co.il				Reference:	2025-02-097714	Time of broadcast: 13:16 13:16

---

The corporation scheduled the publication of the report to 08/12/2025 14:00Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onKamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full- Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026 ����� ����� ����� ������ ������ (����� �� ������� �������) ���� 16:00 ������ https://us02web.zoom.us/webinar/register/WN_FJS1wG_bSUyDPzMQX2wy1A

1765191902_ea026878601_6k_kamadaEDGAR3_Bannerless_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: TASE	Date of revision of form structure: 06/08/2024
Address: Holtzman 2 4081 , Rehovot 7670402   ISRAEL , Tel: 08-9406472 , Fax: 08-9406473
E-mail address: Mosheb@kamada.com   Company site: www.kamada.com
Previous names of reporting entity:
Name of the Signatory: ���� ����� Position of Signatory in the reporting corporation: Name of Employer Company:
Address: �.� ��� , ��� ��� 8532500 Telephone: 054-5392955 Facsimile: 08-9406473 E-mail: aviranm@kamada.com 2